Protection from procarbazine-induced damage of spermatogenesis in the rat by androgen.
Protection of spermatogenesis from cytotoxic drug-induced damage has been investigated in the rat. Complete germinal aplasia was observed at 8 and 11 weeks after four doses of procarbazine hydrochloride administered weekly (150 mg/kg, first dose; 100 mg/kg, 3 subsequent doses). Pretreatment of rats for 6 weeks plus continued treatment during procarbazine administration with testosterone enanthate, 240 micrograms/100 g body weight, resulted in a marked protection of spermatogenesis. A mean of 22% of seminiferous tubule cross-sections at both 8 and 11 weeks exhibited spermatogenesis, and developing spermatids were observed in 60% of these repopulating tubules at the later time. These results provide evidence that protection of spermatogenesis during chemotherapy may be achieved by androgen treatment.
Delic
J I
JI
Bush
C
C
Peckham
M J
MJ
D000728:Androgens / Q000494:pharmacology*; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D005640:Follicle Stimulating Hormone / Q000097:blood; D005837:Genitalia, Male / Q000187:drug effects / Q000473:pathology; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009929:Organ Size / Q000187:drug effects; D011344:Procarbazine / Q000633:toxicity*; D051381:Rats; D011919:Rats, Inbred Strains; D013091:Spermatogenesis / Q000187:drug effects*; D013739:Testosterone / Q000031:analogs & derivatives / Q000494:pharmacology
D000728:Androgens; D011344:Procarbazine; D013739:Testosterone; C004648:testosterone enanthate; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone